Swissmedic grants Lonza in Visp another establishment licence for the production of COVID-19 active substances
Bern, 15.3.2021 - New production site approved for Moderna's COVID-19 vaccine: Swissmedic, the Swiss Agency for Therapeutic Products, has granted the chemicals and pharmaceuticals company Lonza an establishment licence for a new production site for the manufacture of Moderna's COVID-19 active substance. The licence was issued last week following a successful inspection of the production plant in Visp. At this newly approved site Lonza can manufacture, on behalf of Moderna, active substances for COVID-19 vaccines.